Related Experiment Video
Updated: Jun 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy
Jinqi Yan1, Rui Jia, Hongbin Song
1Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Aim:
To develop new approach for tumor immunotherapy with VEGFR2-based DNA vaccine.
Methods:
VEGFR2 derived from different species were prepared by RT-PCR and subjected to recombinant constructs. The chimeric gene of VEGFR2 was prepared by integrating different epitopes in different species. By transfecting into cells, the immunological effect was evaluated with the approaches of ELISA, ELISPOT, and animal experiments.
Results:
(1) All these constructs, in particular chimeric construct, can result in both humoral- and cellular-immune response in BALB/c mice after immunization evaluated by the ratio of CD4+/CD8+ and release of IFN-gamma and IL-4 respectively. (2) Mice were vaccinated with these constructs and challenged with renal carcinoma cells subsequently. It manifested that tumor growth was suppressed significantly in the mice vaccinated by chimeric VEGFR2 construct.
Conclusion:
Our results manifested that VEGFR2-based DNA chimeric vaccine could be developed as a promising approach for tumor immunotherapy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers

